secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2022-03-01T23:59:59+00:00
Accession:  0001558370-22-002558
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q4 net income $280.6M including OMIDRIA gain; adjusted loss $0.37/share
------------------------------------------------------------------------------

- Net income Q4 2021 $280.6M ($4.48/share) includes $184.6M non-cash gain from OMIDRIA royalty capitalization and $126M cash proceeds from sale.
- Adjusted Q4 net loss excluding OMIDRIA divestiture would have been $23.0M ($0.37/share) vs Q3 loss $22.7M ($0.36/share).
- Completed sale of OMIDRIA to Rayner Surgical on Dec 23, 2021 for $126M cash; Omeros retains 50% US royalty until $200M milestone then 30% thereafter.
- Received FDA Complete Response Letter for narsoplimab BLA in TA-TMA in Oct 2021; held Type A meeting in Feb 2022, awaiting FDA response.
- Cash and short-term investments $157.3M at Dec 31, 2021 plus $38.2M accounts receivable expected to be collected in Q1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837022002558/0001558370-22-002558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837022002558/omer-20220301x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-002558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer